ATLANTA, March 20, 2017 /PRNewswire/ -- Global Genomics Group ("G3"), a precision-medicine-based biopharmaceutical companydeveloping genetically validated therapeutics and diagnostics for common, chronic and orphan diseases announced today that the Company's management team will be presenting updated data on their first precision diagnostic biomarker, "knowPLAQUETM",
"knowPLAQUETM" is the first diagnostic blood test that was specifically designed and developed for the identification of patients with any plaque in their coronary arteries. Atherosclerosis is the underlying malevolent abnormality responsible for coronary artery disease, which can result in heart attack, stroke and sudden cardiac death. When patients present with chest pain in the outpatient setting, the test can be used to "rule out" the presence of any plaque in the heart. Positioning this test as a "gatekeeper" to the current clinical evaluation paradigm can eliminate a significant number of unnecessary nuclear stress tests and invasive angiograms, and could save approximately 46% in the costs associated with the evaluation of chest pain patients - possibly saving several billion dollars to the US healthcare system.
"We are very pleased with the outstanding diagnostic performance of "knowPLAQUETM", said Szilard Voros, MD, founder and CEO of Global Genomics Group, who is presenting data on the test at the 2017 Biomarker Summit. "We completed the scientific discovery and validation of this diagnostic biomarker signature, and we are in discussions for the implementation of the test. It is terrific to see that novel, cutting-edge scientific insights can be translated to patient care, which can significantly impact and improve the detection of cardiovascular disease."
"knowPLAQUETM" was discovered and validated in Global Genomics Group's own GLOBAL (Genetic Loci and the Burden of Atherosclerotic Lesions; NCT01738828) clinical study, which recruited a total of approximately 7,500 patients, and the test was developed and validated in a total of 1,096 subjects. The study was specifically designed based on the Institute of Medicine Guidelines and the American Heart Association guidelines for biomarker discovery and validation. Initial results from the study were presented last year at the Society of Cardiovascular Computed Tomography meeting in Orlando, FL.
About Global Genomics Group (G3)
G3 is a global leader in pan-omics and investigates biological networks that lead to the development of disease to identify novel biomarkers and therapeutics. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and systems-biology driven bioinformatics to investigate the development and progression of conditions such as atherosclerosis in cardiovascular disease.
For additional information, please visit www.globalgenomicsgroup.com
G3 Contact:Idean MarvastyVP, Finance and Operationsidean.firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-genomics-group-announces-breakthrough-diagnostic-blood-test-for-plaque-detection-in-the-heart-300425836.html
SOURCE Global Genomics Group (G3)
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All